Literature DB >> 3408506

Anti-IgE autoantibodies in systemic lupus erythematosus. Prevalence and biologic activity.

B L Gruber1, L D Kaufman, M J Marchese, W Roth, A P Kaplan.   

Abstract

IgG and IgM autoantibodies directed against IgE were determined in 95 serum samples from 67 patients with systemic lupus erythematosus, by an enzyme-linked immunosorbent assay. IgM anti-IgE autoantibodies were found in 18 patients (27%) and IgG anti-IgE autoantibodies were detected in 23 patients (34%). The specificity of the immunoassay was confirmed by the ability to inhibit binding with IgE myeloma, but not other immunoglobulin isotypes and the demonstration that the reactivity was directed to the Fc epsilon fragment of IgE. The IgG fraction of certain sera with anti-IgE activity was capable of inducing histamine release from control basophils and cutaneous mast cells. Clinical associations with the presence of anti-IgE activity were sought by retrospective chart analysis of 61 patients. Significant correlation was found with articular involvement, lymphadenopathy, and anti-DNA antibodies (P less than 0.05). Anti-IgE autoantibodies are observed in a significant number of patients with systemic lupus erythematosus and may contribute to the pathogenesis of the vascular and articular lesions characteristic of this disease.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3408506     DOI: 10.1002/art.1780310810

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  15 in total

Review 1.  Current and novel therapeutics in the treatment of systemic lupus erythematosus.

Authors:  Cagri Yildirim-Toruner; Betty Diamond
Journal:  J Allergy Clin Immunol       Date:  2011-02       Impact factor: 10.793

2.  Lpr-induced systemic autoimmunity is unaffected by mast cell deficiency.

Authors:  Annemarie Em van Nieuwenhuijze; Bénédicte Cauwe; Denise Klatt; Stéphanie Humblet-Baron; Adrian Liston
Journal:  Immunol Cell Biol       Date:  2015-04-07       Impact factor: 5.126

3.  Polarization toward Th1-type response in active, but not in inactive, lupus inhibits late allergic rhinitis in lupus-prone female NZB×NZWF(1) mice.

Authors:  Toshiharu Hayashi; Ayumi Murase
Journal:  Inflammation       Date:  2012-12       Impact factor: 4.092

Review 4.  Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection.

Authors:  R R Bartlett; M Dimitrijevic; T Mattar; T Zielinski; T Germann; E Rüde; G H Thoenes; C C Küchle; H U Schorlemmer; E Bremer
Journal:  Agents Actions       Date:  1991-01

5.  IgE-containing immune complexes in synovial fluid of patients with rheumatoid arthritis.

Authors:  L S De Clerck; N J Struyf; C H Bridts; F C Breedveld; M L Westedt; A Cats; W J Stevens
Journal:  Clin Rheumatol       Date:  1990-06       Impact factor: 2.980

Review 6.  Effects of leflunomide on immune responses and models of inflammation.

Authors:  R R Bartlett; H Anagnostopulos; T Zielinski; T Mattar; R Schleyerbach
Journal:  Springer Semin Immunopathol       Date:  1993

7.  Autoantibodies to IgE can induce the release of proinflammatory and vasoactive mediators from human cardiac mast cells.

Authors:  Remo Poto; Vincenzo Patella; Gjada Criscuolo; Gianni Marone; Enrico Coscioni; Gilda Varricchi
Journal:  Clin Exp Med       Date:  2022-07-25       Impact factor: 5.057

8.  Anti-IgE autoantibodies in systemic sclerosis (scleroderma).

Authors:  L D Kaufman; B L Gruber; M J Marchese; J R Seibold
Journal:  Ann Rheum Dis       Date:  1989-03       Impact factor: 19.103

9.  IgE and non-IgE mediated allergic disorders in systemic lupus erythematosus.

Authors:  S Morton; B Palmer; K Muir; R J Powell
Journal:  Ann Rheum Dis       Date:  1998-11       Impact factor: 19.103

10.  Increased IgE serum levels are unrelated to allergic and parasitic diseases in patients with juvenile systemic lupus erythematosus.

Authors:  Bernadete L Liphaus; Adriana A Jesus; Clovis A Silva; Antonio Coutinho; Magda Carneiro-Sampaio
Journal:  Clinics (Sao Paulo)       Date:  2012-11       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.